12,372 trials
Type 2 Diabetes
Primary: Mean Change in HbA1c From Baseline to Week 16 — -0.7; 0.6 percentage
Colorectal Cancer · Colorectal Carcinoma · Colon Cleansing
Primary: Number of Patients With Successful Bowel Cleansing (Overall Colon) — 238; 253; 245; 34 Participants — p=0.055
Diabetes Mellitus, Type 2
Primary: Mean Change in HbA1c From Baseline to Week 16 — -1.0; 0.9 percentage
Parkinson's Disease
Primary: Patient Global Impression (PGI) — 5.2; 5.4; 5.3; 2.8 units on a scale
Dentine Hypersensitivity
Primary: Change From Baseline in Schiff Sensitivity Score on Day 14 — 2.51; 2.51; 1.16; 1.35 score on a scale — p=0.1774
Acellular Pertussis · Tetanus · Diphtheria
Primary: Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T) Antibody Concentrations — 9.207; 21.393; 12.527; 11.07 IU/mL
Breast Neoplasms
Primary: Percentage of Participants With At Least 1 Adverse Event (AE) During the Treatment Period — 88.6; 89.0 percentage of participants
Colorectal Cancer · Colorectal Carcinoma · Colon Cleansing
Primary: Number of Patients With Successful Bowel Cleansing (Overall Colon) — 135; 155; 116; 95 Participants — p=0.038
Influenza, Human
Primary: The Geometric Mean Titer (GMT) Ratio of Each Virus Strain. — 1.01; 1.05; 0.89; 0.92 Ratio
HIV
Primary: Change in Flow-mediated, Endothelium-dependent Vasodilation — 0.2; 0.8 percentage vasodilation
Type 1 Diabetes Mellitus
Primary: Change in Hemoglobin A1c — 2.67; 1.05 percentage change from baseline
Prostate Cancer
Primary: Overall Survival — 5.8; 5.1 years — p=0.15
Purpura, Thrombocytopaenic, Idiopathic
Primary: Overall Summary of On-Therapy Adverse Events (Safety Population) — 277; 96; 133; 41 Participants
Bipolar Disorder · Mania
Primary: Change From Baseline in the Young Mania Rating Scale (YMRS) Total Score at Week 3 — -15.3; -19.6 score on a scale — p=0.0004
Persistent Asthma
Primary: Participants With Treatment-Emergent Adverse Experiences (TEAE) During the Treatment Period — 85; 29; 83; 29 Participants